◎ Sugi Atlas

Atlas / Disease / Neovascular glaucoma

Neovascular glaucoma

disease
On this page

Summary

Neovascular glaucoma (MONDO:0019783) is a disease and 20 clinical trials. Top therapeutic interventions include ranibizumab, travoprost, and aganirsen. A subtype of angle-closure glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
  • Phenotypes (HPO): 20
  • Clinical trials: 20

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Point prevalence1-5 / 10 00024.4EuropeValidated

Signs & symptoms

Clinical features (HPO)

20 HPO clinical features (Orphanet curated; top 20 by frequency):

HPO IDTermFrequency
HP:0000501GlaucomaObligate (100%)
HP:0000572Visual lossVery frequent (80-99%)
HP:0011497Iris neovascularizationVery frequent (80-99%)
HP:0012636Retinal vein occlusionVery frequent (80-99%)
HP:0000488RetinopathyFrequent (30-79%)
HP:0000553Abnormal uvea morphologyFrequent (30-79%)
HP:0000587Abnormal optic nerve morphologyFrequent (30-79%)
HP:0000613PhotophobiaFrequent (30-79%)
HP:0007906Ocular hypertensionFrequent (30-79%)
HP:0020166Central retinal vein occlusionFrequent (30-79%)
HP:0030532Visual acuity test abnormalityFrequent (30-79%)
HP:0200026Ocular painFrequent (30-79%)
HP:3000032Abnormality of central retinal arteryFrequent (30-79%)
HP:0000593Abnormal anterior chamber morphologyOccasional (5-29%)
HP:0004329Abnormality of the posterior segment of the globeOccasional (5-29%)
HP:0007850Retinal vascular proliferationOccasional (5-29%)
HP:0012040Corneal stromal edemaOccasional (5-29%)
HP:0025358Uveal ectropionOccasional (5-29%)
HP:0030953Conjunctival hyperemiaOccasional (5-29%)
HP:0000541Retinal detachmentVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameneovascular glaucoma
Mondo IDMONDO:0019783
EFOEFO:1001060
MeSHD015355
Orphanet94058
DOIDDOID:1687
ICD-11700864997
SNOMED CT232086000
UMLSC0017609
MedGen4898
GARD0019245
MedDRA10062891
Is cancer (heuristic)no

Disease family

This is a subtype of angle-closure glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › glaucoma › angle-closure glaucoma › neovascular glaucoma

Related subtypes (1): primary angle-closure glaucoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AfliberceptPhase 3 (in late-stage trials)
RanibizumabPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Mitomycin, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified13
PHASE23
PHASE31
PHASE2/PHASE31
PHASE1/PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00524758PHASE3COMPLETEDOculusgen (Ologen) Glaucoma MMC Control in Estonia
NCT02947867PHASE2/PHASE3UNKNOWNTrial of Aganirsen in iCRVO Patients at Risk of Developing NVG
NCT00727038PHASE1/PHASE2WITHDRAWNLucentis for New Onset Neovascular Glaucoma
NCT01051583PHASE2COMPLETEDAvastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma
NCT02067013PHASE2UNKNOWNAnalysis of Aqueous and Vitreous Humor
NCT02805257PHASE2COMPLETEDAhmed Glaucoma Valve Surgery With Mitomycin-C
NCT04844619PHASE1ACTIVE_NOT_RECRUITINGKDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
NCT04519619Not specifiedRECRUITINGStudy to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
NCT05316142Not specifiedACTIVE_NOT_RECRUITINGEffect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma
NCT07201415Not specifiedACTIVE_NOT_RECRUITINGMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma
NCT00441181Not specifiedWITHDRAWNEffects of Travoprost on Neovascular Glaucoma
NCT00491712Not specifiedUNKNOWNComparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection
NCT01301378Not specifiedTERMINATEDPatch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube
NCT01370135Not specifiedCOMPLETEDStudy to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma
NCT01711879Not specifiedCOMPLETEDUse of Intravitreal Aflibercept Injection for Neovascular Glaucoma
NCT02260219Not specifiedTERMINATEDComparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma
NCT03154892Not specifiedCOMPLETEDThe Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
NCT04970251Not specifiedCOMPLETEDAflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
NCT05156021Not specifiedCOMPLETEDA Study on the Treatment Strategy of NVG Secondary to PDR
NCT07177807Not specifiedCOMPLETEDClinical Characteristics of Neovascular Glaucoma

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
RANIBIZUMAB42
TRAVOPROST41
AGANIRSEN21

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogardgenccgwasgwas_studyhgncicd11meddramedgenmeshmimmondomondochildmondoparentorphanetsctidumls